Karyopharm Therapeutics (KPTI) Cash & Equivalents (2012 - 2026)
Karyopharm Therapeutics' Cash & Equivalents came in at $54.98 million for Q2 2026, up 42.0% from $38.73 million a year earlier.
Powered by 
Analysis
Karyopharm Therapeutics (KPTI) Cash & Equivalents (2012 - 2026) Analysis & Trends
At the end of FY2025, Karyopharm Therapeutics' Cash & Equivalents was $60.54 million, down 3.1% from FY2024.
- Cash & Equivalents carries a five-year compound annual growth rate of -6.8% (FY2020 to FY2025).
- Going back by year, Cash & Equivalents was $62.48 million in FY2024 (+19.6%), $52.23 million in FY2023 (-61.4%), $135.19 million in FY2022 (-29.0%) and $190.46 million in FY2021 (+121.7%).
- The five-year range for quarterly Cash & Equivalents is $30.63 million (Q1 2024) to $190.46 million (Q4 2021).
- Year-over-year, Cash & Equivalents increased in four of the last seven quarters, with growth averaging 7.1%.
- The fastest year-over-year change in Cash & Equivalents over five years came in Q4 2021 (growth of 121.7%), and the weakest in Q1 2024 (a decline of 63.6%).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,199.50 Bn | 1,168.08 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 635.17 Bn | 555.03 Bn | 17.30 Bn | 16.91 Bn |
| 3 | AbbVie | 504.69 Bn | 477.85 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 358.43 Bn | 312.86 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 288.36 Bn | 252.75 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 265.78 Bn | 239.54 Bn | 12.86 Bn | 4.90 Bn |
| 7 | Amgen | 237.46 Bn | 192.86 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 193.65 Bn | 167.76 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 171.05 Bn | 118.00 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Karyopharm Therapeutics | 15.05 Mn | -211.38 Mn | 32.35 Mn | 54.98 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 54.98 Mn |
| Dec 31, 2025 | 60.54 Mn |
| Sep 30, 2025 | 37.67 Mn |
| Jun 30, 2025 | 38.73 Mn |
| Mar 31, 2025 | 38.78 Mn |
| Dec 31, 2024 | 62.48 Mn |
| Sep 30, 2024 | 72.83 Mn |
| Jun 30, 2024 | 84.77 Mn |
| Mar 31, 2024 | 30.63 Mn |
| Dec 31, 2023 | 52.23 Mn |
| Sep 30, 2023 | 43.66 Mn |
| Jun 30, 2023 | 80.89 Mn |
| Mar 31, 2023 | 84.06 Mn |
| Dec 31, 2022 | 135.19 Mn |
| Sep 30, 2022 | 71.35 Mn |
| Jun 30, 2022 | 82.25 Mn |
| Mar 31, 2022 | 153.26 Mn |
| Dec 31, 2021 | 190.46 Mn |
| Sep 30, 2021 | 137.40 Mn |
| Jun 30, 2021 | 141.31 Mn |
API Access
Karyopharm Therapeutics Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=KPTI&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "KPTI", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=KPTI&period=max&api_key=YOUR_API_KEY");
const data = await res.json();